Aspira Women's Health Inc. (AWH) News
Filter AWH News Items
AWH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AWH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AWH News From Around the Web
Below are the latest news stories about ASPIRA WOMEN'S HEALTH INC that investors may wish to consider to help them evaluate AWH as an investment opportunity.
Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial OperationsInterim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic ... |
Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEOCEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transitionAUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matt |
Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million AwardThe Company received the first $2 million from the ARPA-H Sprint for Women’s Health AwardAUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash |
Aspira Womens Health Inc (AWH) Q3 2024 Earnings Call Highlights: Strategic Wins Amidst Market ...Aspira Womens Health Inc (AWH) reports growth in test volumes and secures a $10 million federal award, despite weather-related setbacks. |
Aspira Women’s Health Reports Selected Third Quarter 2024 Financial ResultsQ3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development |
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New JerseyAUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-owned subsidiary of OPKO |
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024Management to Announce Earnings Results and hold a call at 8:30 am ETAUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call |
Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipelineAUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 20 |
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s HealthAspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosisAUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health to address critical unmet challenges in wome |
Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York StateAUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Progra |